|
|
Medarex News (NASDAQ:MEDX)
| Latest Medarex News Headlines | | Date | Time | Source | | | 11/03/2008 | 7:00AM | PRNUS | Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Comb
Top-line data from randomized, double-blind, placebo controlled Phase 2 clinical trial indicate statistically significant reduction in recurrences of CDAD
PRINCETON, N.J. and JAMAICA PLAIN, Mass., Nov. 3 /PRNewswire-FirstCall/ -- Medarex, Inc. (NASDAQ:MEDX) and The Massachusetts Biologic Laboratories (MBL) of the University... More...>> |
| 10/30/2008 | 4:00PM | PRNUS | Medarex Announces 2008 Third Quarter Financial Results
PRINCETON, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Medarex, Inc. (NASDAQ:MEDX) announced today its financial results for the quarter ended September 30, 2008.
Medarex's net loss for the quarter ended September 30, 2008 was $45.7 million, or ($0.36) per share, as compared to a net loss of $51.6 million, or ($0.41) per... More...>> |
| 10/30/2008 | 4:00PM | PRNUS | Medarex Announces 2008 Third Quarter Financial Results
PRINCETON, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Medarex, Inc. (NASDAQ:MEDX) announced today its financial results for the quarter ended September 30, 2008.
Medarex's net loss for the quarter ended September 30, 2008 was $45.7 million, or ($0.36) per share, as compared to a net loss of $51.6 million, or ($0.41) per... More...>> |
| 10/28/2008 | 8:00AM | PRNUS | Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
- Data Presentation at 48th ICAAC / IDSA 46th Annual Meeting -
PRINCETON, N.J. and ANNAPOLIS, Md., Oct. 28 /PRNewswire-FirstCall/ -- Medarex, Inc. (NASDAQ:MEDX), a leading monoclonal antibody company, and PharmAthene, Inc. (NYSE:PIP), a biodefense company developing medical countermeasures against biological and chemical... More...>> |
| 09/24/2008 | 9:00AM | PRNUS | PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
ANNAPOLIS, Md., Sept. 24 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (AMEX:PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company is presenting two posters and an oral presentation on its medical countermeasures programs, Protexia(R) (rBChE... More...>> |
| 09/17/2008 | 4:00PM | PRNUS | Medarex to Present at the UBS Global Life Sciences Conference
PRINCETON, N.J., Sept. 17 /PRNewswire-FirstCall/ -- Medarex, Inc. (NASDAQ:MEDX) announced today that it is scheduled to present at the UBS Global Life Sciences Conference at 4:30 p.m. Eastern Time on Monday, September 22, 2008. The event will be webcast live and will be available in the Investor Relations section of... More...>> |
| 09/08/2008 | 8:00AM | PRNUS | Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
PRINCETON, N.J., Sept. 8 /PRNewswire-FirstCall/ -- Medarex, Inc. (NASDAQ:MEDX) today announced that it received a milestone payment for an undisclosed amount from its licensing partner, Pfizer Inc. (NYSE:PFE). This payment is a result of the submission of an Investigational New Drug (IND) application by Pfizer for the... More...>> |
| 09/04/2008 | 8:00AM | PRNUS | Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
Updated Survival Data for Ipilimumab to be Presented
PRINCETON, N.J., Sept. 4 /PRNewswire-FirstCall/ -- Medarex, Inc. (NASDAQ:MEDX) announced today that nine clinical abstracts for ipilimumab, an investigational anti-CTLA-4 antibody, in melanoma are scheduled to be the subject of presentations at the 33rd Congress of... More...>> |
| 09/02/2008 | 4:00PM | PRNUS | Medarex to Present at the Thomas Weisel Partners Healthcare Conference
PRINCETON, N.J., Sept. 2 /PRNewswire-FirstCall/ -- Medarex, Inc. (NASDAQ:MEDX) announced today that it is scheduled to present at the Thomas Weisel Partners Healthcare Conference at 9:10 a.m. Eastern Time on Thursday, September 4, 2008. The event will be webcast live and will be available in the Investor Relations section... More...>> |
| 08/12/2008 | 10:00AM | PRNUS | Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
Medarex to Receive Milestone Payment from MedImmune
PRINCETON, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Medarex, Inc. (NASDAQ:MEDX) announced today that its partner MedImmune, Inc. has initiated a Phase 2A multi-dose clinical trial of MEDI-545 for the potential treatment of systemic lupus erythematosus (SLE or lupus... More...>> |
| 08/05/2008 | 4:09PM | PRNUS | Medarex Announces 2008 Second Quarter Financial Results
PRINCETON, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Medarex, Inc. (NASDAQ:MEDX) announced today its financial results for the quarter ended June 30, 2008.
Medarex's net loss for the quarter ended June 30, 2008 was $53.1 million, or ($0.42) per share as compared to a net loss of $41.0 million, or ($0.32) per share for... More...>> |
| 08/05/2008 | 8:00AM | PRNUS | Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
Clinical study planned for advanced or recurrent solid tumors
PRINCETON, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Medarex, Inc. (NASDAQ:MEDX) announced today the allowance of an investigational new drug application (IND) filed with the U.S. Food & Drug Administration (FDA) for MDX-1105, for the treatment of patients with... More...>> |
| 07/23/2008 | 8:00AM | PRNUS | Medarex Receives Milestone Payment for Acceptance of Investigational New Drug Application
PRINCETON, N.J., July 23 /PRNewswire-FirstCall/ -- Medarex, Inc. (NASDAQ:MEDX) today announced that it has received a milestone payment of an undisclosed amount from its licensing partner, Centocor R&D Inc., for the acceptance of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration... More...>> |
| 07/16/2008 | 6:00AM | PRNUS | BioWa and Medarex Announce License of BioWa's COMPLEGENT(TM) Technology
PRINCETON, N.J., July 16 /PRNewswire-FirstCall/ -- BioWa, Inc. and Medarex, Inc. (NASDAQ:MEDX) announced today that they have entered into a license agreement which provides Medarex with the first ever access to BioWa's COMPLEGENT(TM) Technology for enhancing the complement-dependent cytotoxicity (CDC) of select Medarex... More...>> |
| 07/10/2008 | 3:54PM | PRNUS | Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
PRINCETON, N.J., July 10 /PRNewswire-FirstCall/ -- Medarex, Inc. (NASDAQ:MEDX) today provided a detailed overview of the company's strategy, strength in research discovery and antibody development, and the multiple opportunities Medarex is engaged in for creating long-term value. In addition, comprehensive updates on... More...>> |
| 07/07/2008 | 12:26PM | PRNUS | Medarex Announces July 10 Live Webcast of R&D Day Event
PRINCETON, N.J., July 7 /PRNewswire-FirstCall/ -- Medarex, Inc. (NASDAQ:MEDX) invites investors, the media and the general public to listen to a live webcast of its 2008 R&D Day event. The webcast will begin on Thursday, July 10, 2008 at 8:00 a.m. Eastern Time and is expected to last approximately four hours. Members... More...>> |
| 06/18/2008 | 7:00AM | PRNUS | Medarex to Present at the Jefferies Second Annual Healthcare Conference
PRINCETON, N.J., June 18 /PRNewswire-FirstCall/ -- Medarex, Inc. (NASDAQ:MEDX) announced today that it is scheduled to present at the Jefferies Second Annual Healthcare Conference at 11:15 a.m. Eastern Time on Wednesday, June 25, 2008. The event will be webcast live and will be available in the Investor Relations section... More...>> |
| 06/03/2008 | 7:00AM | PRNUS | Medarex to Present at the 29th Annual Goldman Sachs Healthcare Conference
PRINCETON, N.J., June 3 /PRNewswire-FirstCall/ -- Medarex, Inc. (NASDAQ:MEDX) announced today that it is scheduled to present at the 29th Annual Goldman Sachs Healthcare Conference at 1:25 p.m. Eastern Time on Tuesday, June 10, 2008. The event will be webcast live and will be available in the Investor Relations section... More...>> |
| 06/02/2008 | 12:30PM | PRNUS | Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting
PRINCETON, N.J., June 2 /PRNewswire-FirstCall/ -- Medarex, Inc. (NASDAQ:MEDX) today announced interim results from a Phase 1/2 trial of ipilimumab, an investigational oncology immunotherapy, as monotherapy or in combination with radiotherapy in patients with metastatic castration resistant prostate cancer (mCRPC). Data... More...>> |
| 06/02/2008 | 6:30AM | PRNUS | Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncol
PRINCETON, N.J., June 2 /PRNewswire-FirstCall/ -- Medarex, Inc. (NASDAQ:MEDX) today announced preliminary data from an ongoing Phase 1 study of MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human anti-PD-1 antibody. Data presented from patients with recurrent or treatment-refractory... More...>> |
|
|
|